• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Autologous stem cell transplantation in hematological malignancies.

作者信息

Gorin Norbert-Claude

机构信息

Department of Hematology and Cell Therapy, and EBMT Paris office, Hôpital Saint-Antoine and Université Pierre et Marie Curie, 75012 Paris, France.

出版信息

Springer Semin Immunopathol. 2004 Nov;26(1-2):3-30. doi: 10.1007/s00281-004-0172-4. Epub 2004 Oct 7.

DOI:10.1007/s00281-004-0172-4
PMID:15480668
Abstract
摘要

相似文献

1
Autologous stem cell transplantation in hematological malignancies.血液系统恶性肿瘤中的自体干细胞移植。
Springer Semin Immunopathol. 2004 Nov;26(1-2):3-30. doi: 10.1007/s00281-004-0172-4. Epub 2004 Oct 7.
2
[The impact of stem cell therapy in hematology and oncology].
Internist (Berl). 2006 May;47(5):467-8, 470-8. doi: 10.1007/s00108-006-1601-3.
3
Autologous peripheral blood stem cell transplantation in the patients with hematologic malignancies and solid tumors.血液系统恶性肿瘤和实体瘤患者的自体外周血干细胞移植
Chin Med J (Engl). 2001 Feb;114(2):196-9.
4
High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma.
Prog Clin Biol Res. 1994;389:505-11.
5
Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.对淋巴增殖性恶性肿瘤患者进行自体外周血祖细胞移植后，进行定期的形态学、细胞遗传学和克隆性评估。
Haematologica. 2002 Jan;87(1):59-66.
6
[An analysis of double autologous hemopoietic stem cell transplantation for hematological malignancies].
Zhonghua Yi Xue Za Zhi. 2002 Jan 25;82(2):123-6.
7
Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.对于低度非霍奇金淋巴瘤患者，利妥昔单抗用于自体干细胞治疗时的“体内净化”不会影响干细胞功能及植入。
Semin Oncol. 1999 Oct;26(5 Suppl 14):115-22.
8
Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.大剂量白消安和环磷酰胺序贯自体外周血干细胞移植治疗血液系统恶性肿瘤的Ⅰ-Ⅱ期研究：毒性反应与造血恢复情况
Bone Marrow Transplant. 1996 Jul;18(1):9-14.
9
Autologous bone marrow transplantation for leukemia.白血病的自体骨髓移植
Semin Oncol. 1993 Oct;20(5 Suppl 6):40-54.
10
Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.以净化骨髓进行自体干细胞移植作为高肿瘤负荷滤泡性淋巴瘤一线治疗的价值：一项GOELAMS二期研究
Bone Marrow Transplant. 2000 Nov;26(9):971-7. doi: 10.1038/sj.bmt.1702631.

引用本文的文献

1
Value of pretransplant pulmonary function tests in predicting pulmonary complications after autologous peripheral stem cell transplantation.移植前肺功能测试在预测自体外周血干细胞移植后肺部并发症中的价值。
Lung. 2007 Dec;185(6):321-4. doi: 10.1007/s00408-007-9047-5. Epub 2007 Oct 19.
2
Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.环磷酰胺（4 g/m²）后给予低剂量粒细胞-巨噬细胞集落刺激因子（莫拉司亭）和粒细胞集落刺激因子（非格司亭）可提高外周血祖细胞采集量：两项纳入120例患者的随机研究结果
Bone Marrow Transplant. 2006 Aug;38(4):275-84. doi: 10.1038/sj.bmt.1705441.

本文引用的文献

1
Ex vivo expansion of mafosfamide-purged PBPC products.
Cytotherapy. 2006;8(5):459-64. doi: 10.1080/14653240600905353.
2
Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.沙利度胺的免疫调节类似物：骨髓瘤治疗的新兴疗法
J Clin Oncol. 2004 Aug 15;22(16):3212-4. doi: 10.1200/JCO.2004.05.984. Epub 2004 Jul 12.
3
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.沙利度胺单独或与地塞米松联合用于晚期、复发或难治性多发性骨髓瘤合并肾衰竭患者。
Eur J Haematol. 2004 Aug;73(2):98-103. doi: 10.1111/j.1600-0609.2004.00272.x.
4
Development of the proteasome inhibitor Velcade (Bortezomib).蛋白酶体抑制剂万珂（硼替佐米）的研发。
Cancer Invest. 2004;22(2):304-11. doi: 10.1081/cnv-120030218.
5
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.非清髓性异基因造血移植：一种有前景的挽救性治疗方法，用于非霍奇金淋巴瘤患者，这些患者的疾病在先前的自体移植中治疗失败。
J Clin Oncol. 2004 Jun 15;22(12):2419-23. doi: 10.1200/JCO.2004.09.092.
6
Overview of transplant activity in Europe.欧洲移植活动概述。
Hematol J. 2004;5 Suppl 3:S29-33. doi: 10.1038/sj.thj.6200418.
7
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.淋巴细胞淋巴瘤采用高剂量环磷酰胺、长春新碱、多柔比星和地塞米松（hyper-CVAD）方案的治疗结果。
Blood. 2004 Sep 15;104(6):1624-30. doi: 10.1182/blood-2003-12-4428. Epub 2004 Jun 3.
8
A review of the proteasome inhibitor bortezomib in multiple myeloma.蛋白酶体抑制剂硼替佐米在多发性骨髓瘤中的研究综述
Expert Opin Pharmacother. 2004 Jun;5(6):1321-31. doi: 10.1517/14656566.5.6.1321.
9
Small molecule FLT3 tyrosine kinase inhibitors.小分子FLT3酪氨酸激酶抑制剂
Curr Pharm Des. 2004;10(11):1183-93. doi: 10.2174/1381612043452604.
10
An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.自体或异基因干细胞移植的大剂量疗法在套细胞淋巴瘤中的作用的最新进展。
Curr Opin Oncol. 2004 Mar;16(2):106-13. doi: 10.1097/00001622-200403000-00004.